Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:heteroarene
go back to main search page
Accession:CHEBI:33833 term browser browse the term
Definition:A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2).
Synonyms:exact_synonym: heteroarenes
 related_synonym: hetarenes



show annotations for term's descendants           Sort by:
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2RY2 purinergic receptor P2Y2 multiple interactions EXP [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] CTD PMID:10604969 NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
JBrowse link
3'-CMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions EXP [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
JBrowse link
3-isobutyl-1-methyl-7H-xanthine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CFTR CF transmembrane conductance regulator multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein CTD PMID:15161604 NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
JBrowse link
7,9-dihydro-1H-purine-2,6,8(3H)-trione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP6V0D1 ATPase H+ transporting V0 subunit d1 increases expression EXP Uric Acid results in increased expression of ATP6V0D1 protein CTD PMID:32991862 NCBI chr 5:81,926,589...81,965,959
Ensembl chr 5:81,926,612...81,965,526
JBrowse link
G DNAJC3 DnaJ heat shock protein family (Hsp40) member C3 increases expression EXP Uric Acid results in increased expression of DNAJC3 protein CTD PMID:32991862 NCBI chr22:46,323,263...46,402,240
Ensembl chr22:46,307,905...46,398,625
JBrowse link
G EEF2 eukaryotic translation elongation factor 2 decreases expression EXP Uric Acid results in decreased expression of EEF2 protein CTD PMID:32991862 NCBI chr20:55,577,413...55,586,422
Ensembl chr20:55,522,213...55,586,126
JBrowse link
G EZR ezrin increases expression EXP Uric Acid results in increased expression of EZR protein CTD PMID:32991862 NCBI chr 1:48,160,206...48,210,036
Ensembl chr 1:48,160,206...48,210,036
JBrowse link
G HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1 increases expression EXP Uric Acid results in increased expression of HNRNPA2B1 protein CTD PMID:32991862 NCBI chr14:39,498,805...39,509,034
Ensembl chr14:39,500,897...39,508,952
JBrowse link
G HSP90AA1 heat shock protein 90 alpha family class A member 1 increases expression EXP Uric Acid results in increased expression of HSP90AA1 protein CTD PMID:32991862 NCBI chr 8:70,091,203...70,096,107
Ensembl chr 8:70,092,217...70,095,243
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP Uric Acid results in increased expression of HSPA5 protein CTD PMID:32991862 NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
JBrowse link
G HSPD1 heat shock protein family D (Hsp60) member 1 decreases expression EXP Uric Acid results in decreased expression of HSPD1 protein CTD PMID:32991862 NCBI chr37:7,010,421...7,025,912 JBrowse link
G IMMT inner membrane mitochondrial protein increases expression EXP Uric Acid results in increased expression of IMMT protein CTD PMID:32991862 NCBI chr17:38,927,508...38,964,522
Ensembl chr17:38,927,531...38,967,004
JBrowse link
G LOC102151342 ATP synthase subunit d, mitochondrial-like increases expression EXP Uric Acid results in increased expression of ATP5PD protein CTD PMID:32991862 NCBI chr 7:66,856,651...66,857,162 JBrowse link
G MDH2 malate dehydrogenase 2 decreases expression EXP Uric Acid results in decreased expression of MDH2 protein CTD PMID:32991862 NCBI chr 6:7,389,266...7,405,311 JBrowse link
G NAPA NSF attachment protein alpha decreases expression EXP Uric Acid results in decreased expression of NAPA protein CTD PMID:32991862 NCBI chr 1:108,510,920...108,533,317
Ensembl chr 1:108,510,931...108,532,881
JBrowse link
G OAT ornithine aminotransferase increases expression EXP Uric Acid results in increased expression of OAT protein CTD PMID:32991862 NCBI chr28:33,763,661...33,788,817
Ensembl chr28:33,758,473...33,788,759
JBrowse link
G PC pyruvate carboxylase decreases expression EXP Uric Acid results in decreased expression of PC protein CTD PMID:32991862 NCBI chr18:50,406,994...50,507,677
Ensembl chr18:50,412,272...50,507,669
JBrowse link
G RAB11A RAB11A, member RAS oncogene family decreases expression EXP Uric Acid results in decreased expression of RAB11A protein CTD PMID:32991862 NCBI chr30:30,200,831...30,218,412
Ensembl chr30:30,200,831...30,218,411
JBrowse link
G SAE1 SUMO1 activating enzyme subunit 1 decreases expression EXP Uric Acid results in decreased expression of SAE1 protein CTD PMID:32991862 NCBI chr 1:108,757,543...108,864,763
Ensembl chr 1:108,749,061...108,859,797
JBrowse link
G SLC25A12 solute carrier family 25 member 12 decreases expression EXP Uric Acid results in decreased expression of SLC25A12 protein CTD PMID:32991862 NCBI chr36:16,185,011...16,391,080
Ensembl chr36:16,185,649...16,483,016
JBrowse link
G SLC2A9 solute carrier family 2 member 9 increases transport EXP SLC2A9 protein results in increased transport of Uric Acid CTD PMID:18989453 NCBI chr 3:69,394,304...69,588,462
Ensembl chr 3:69,394,152...69,595,802
JBrowse link
8-(4-chlorophenylthio)-cAMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CFTR CF transmembrane conductance regulator multiple interactions EXP [1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein CTD PMID:15161604 NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
JBrowse link
acyclovir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AVP arginine vasopressin decreases activity EXP Acyclovir results in decreased activity of AVP protein CTD PMID:2724137 NCBI chr24:18,183,057...18,184,827
Ensembl chr24:18,183,057...18,184,883
JBrowse link
antipyrine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP Antipyrine results in decreased activity of PTGS1 protein alternative form CTD PMID:12242329 NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
JBrowse link
cilostazol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G MYC MYC proto-oncogene, bHLH transcription factor decreases expression EXP Cilostazol results in decreased expression of MYC mRNA CTD PMID:19545562 NCBI chr13:25,200,772...25,205,309
Ensembl chr13:25,200,577...25,205,309
JBrowse link
cimetidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A2 solute carrier family 22 member 2 decreases activity EXP Cimetidine results in decreased activity of SLC22A2 protein CTD PMID:36669674 NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
JBrowse link
clotrimazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases activity EXP Clotrimazole results in increased activity of NR1I2 protein CTD PMID:27732639 NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
JBrowse link
G NR1I3 nuclear receptor subfamily 1 group I member 3 affects binding
increases activity
EXP Clotrimazole binds to NR1I3 protein
Clotrimazole results in increased activity of NR1I3 protein; Clotrimazole results in increased activity of NR1I3 protein mutant form
CTD PMID:21778469 PMID:27732639 NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
JBrowse link
cytidine 5'-monophosphate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDIPT CDP-diacylglycerol--inositol 3-phosphatidyltransferase multiple interactions EXP [delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate CTD PMID:2579070 NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
JBrowse link
dexmedetomidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NISCH nischarin affects activity EXP Dexmedetomidine affects the activity of NISCH CTD PMID:7486159 NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
JBrowse link
edaravone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SELP selectin P decreases expression EXP Edaravone results in decreased expression of SELP protein CTD PMID:16041266 NCBI chr 7:28,956,428...28,997,266
Ensembl chr 7:28,958,486...28,996,313
JBrowse link
fomepizole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions EXP Fomepizole inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene] CTD PMID:8592870 NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
JBrowse link
hexaconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC47A1 solute carrier family 47 member 1 decreases activity EXP hexaconazole results in decreased activity of SLC47A1 protein CTD PMID:36669674 NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
JBrowse link
G SLC47A2 solute carrier family 47 member 2 decreases activity EXP hexaconazole results in decreased activity of SLC47A2 protein CTD PMID:36669674 NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
JBrowse link
imidazoles term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NR1I3 nuclear receptor subfamily 1 group I member 3 decreases activity
multiple interactions
EXP Imidazoles results in decreased activity of NR1I3 protein alternative form
artemisinin inhibits the reaction [Imidazoles results in decreased activity of NR1I3 protein alternative form]; Imidazoles inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form]
CTD PMID:21778469 NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
JBrowse link
indometacin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HEXB hexosaminidase subunit beta multiple interactions EXP Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein] CTD PMID:21671308 NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 decreases activity EXP Indomethacin results in decreased activity of PTGS1 protein alternative form CTD PMID:12242329 NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
JBrowse link
indoxyl sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A6 solute carrier family 22 member 6 multiple interactions EXP [Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Pantoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican CTD PMID:36243147 NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
JBrowse link
iprodione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor multiple interactions EXP [iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein CTD PMID:24389113 NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP [iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein CTD PMID:24389113 NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
JBrowse link
isatin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CPNE6 copine 6 increases reduction EXP DHRS4 protein results in increased reduction of Isatin CTD PMID:17827741 NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
JBrowse link
ketoconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 decreases expression
multiple interactions
decreases activity
EXP Ketoconazole results in decreased expression of ABCB1 mRNA
[Ketoconazole results in decreased activity of ABCB1 protein] which results in decreased transport of Technetium Tc 99m Sestamibi
CTD PMID:19754906 PMID:22620706 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
G CYP3A12 cytochrome P-450 3A12 multiple interactions
decreases activity
EXP Ketoconazole inhibits the reaction [CYP3A12 protein results in increased hydroxylation of Diazepam]
Ketoconazole results in decreased activity of CYP3A12 protein
CTD PMID:15677349
losartan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G REN renin increases expression EXP Losartan results in increased expression of REN protein CTD PMID:10483973 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
losartan carboxylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G REN renin increases expression EXP losartan carboxylic acid results in increased expression of REN protein CTD PMID:10483973 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
masitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA5 ATP binding cassette subfamily A member 5 increases expression EXP masitinib results in increased expression of ABCA5 mRNA CTD PMID:22747577 NCBI chr 9:15,708,070...15,781,100
Ensembl chr 9:15,420,835...15,783,045
JBrowse link
G ABHD14A abhydrolase domain containing 14A increases expression EXP masitinib results in increased expression of ABHD14A mRNA CTD PMID:22747577 NCBI chr20:37,738,500...37,744,689 JBrowse link
G ABITRAM actin binding transcription modulator decreases expression EXP masitinib results in decreased expression of ABITRAM mRNA CTD PMID:22747577 NCBI chr11:64,094,653...64,100,078
Ensembl chr11:64,094,721...64,109,421
JBrowse link
G ABLIM1 actin binding LIM protein 1 increases expression EXP masitinib results in increased expression of ABLIM1 mRNA CTD PMID:22747577 NCBI chr28:25,260,323...25,543,369
Ensembl chr28:25,260,873...25,545,304
JBrowse link
G ACAT2 acetyl-CoA acetyltransferase 2 decreases expression EXP masitinib results in decreased expression of ACAT2 mRNA CTD PMID:22747577 NCBI chr 1:49,011,665...49,029,368
Ensembl chr 1:49,011,706...49,029,327
JBrowse link
G ACSM3 acyl-CoA synthetase medium chain family member 3 increases expression EXP masitinib results in increased expression of ACSM3 mRNA CTD PMID:22747577 NCBI chr 6:24,558,010...24,594,326
Ensembl chr 6:24,558,142...24,582,728
JBrowse link
G ACTL7A actin like 7A increases expression EXP masitinib results in increased expression of ACTL7A mRNA CTD PMID:22747577 NCBI chr11:64,031,305...64,033,908
Ensembl chr11:64,032,358...64,033,788
JBrowse link
G ACTR2 actin related protein 2 decreases expression EXP masitinib results in decreased expression of ACTR2 protein CTD PMID:22747577 NCBI chr10:64,696,068...64,733,027
Ensembl chr10:64,696,111...64,730,553
JBrowse link
G ADPRH ADP-ribosylarginine hydrolase increases expression EXP masitinib results in increased expression of ADPRH mRNA CTD PMID:22747577 NCBI chr33:23,218,633...23,226,844
Ensembl chr33:23,218,101...23,224,667
JBrowse link
G AGA aspartylglucosaminidase increases expression EXP masitinib results in increased expression of AGA mRNA CTD PMID:22747577 NCBI chr16:52,314,860...52,324,879
Ensembl chr16:52,314,535...52,324,894
JBrowse link
G AGO2 argonaute RISC catalytic component 2 decreases expression EXP masitinib results in decreased expression of AGO2 mRNA CTD PMID:22747577 NCBI chr13:35,169,243...35,230,252
Ensembl chr13:35,180,912...35,268,577
JBrowse link
G AGRN agrin increases expression EXP masitinib results in increased expression of AGRN mRNA CTD PMID:22747577 NCBI chr 5:56,239,621...56,273,679
Ensembl chr 5:56,239,701...56,272,745
JBrowse link
G AIG1 androgen induced 1 increases expression EXP masitinib results in increased expression of AIG1 mRNA CTD PMID:22747577 NCBI chr 1:34,643,994...34,884,445
Ensembl chr 1:34,643,764...34,884,119
JBrowse link
G ALAS2 5'-aminolevulinate synthase 2 increases expression EXP masitinib results in increased expression of ALAS2 mRNA CTD PMID:22747577 NCBI chr  X:46,703,477...46,731,767
Ensembl chr  X:46,703,477...46,723,529
JBrowse link
G ALDH5A1 aldehyde dehydrogenase 5 family member A1 decreases expression EXP masitinib results in decreased expression of ALDH5A1 mRNA CTD PMID:22747577 NCBI chr35:22,560,005...22,590,996
Ensembl chr35:22,560,008...22,587,875
JBrowse link
G AMN1 antagonist of mitotic exit network 1 homolog increases expression EXP masitinib results in increased expression of AMN1 mRNA CTD PMID:22747577 NCBI chr27:17,044,301...17,100,444
Ensembl chr27:17,044,309...17,361,570
JBrowse link
G ANKRD26 ankyrin repeat domain containing 26 increases expression EXP masitinib results in increased expression of ANKRD26 mRNA CTD PMID:22747577 NCBI chr 2:6,230,466...6,402,360 JBrowse link
G ANP32E acidic nuclear phosphoprotein 32 family member E decreases expression EXP masitinib results in decreased expression of ANP32E mRNA CTD PMID:22747577 NCBI chr17:59,460,864...59,482,467
Ensembl chr17:59,462,766...59,477,936
JBrowse link
G ANXA1 annexin A1 increases expression EXP masitinib results in increased expression of ANXA1 protein CTD PMID:22747577 NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011
JBrowse link
G ANXA6 annexin A6 increases expression EXP masitinib results in increased expression of ANXA6 protein CTD PMID:22747577 NCBI chr 4:58,091,186...58,140,102
Ensembl chr 4:58,091,251...58,139,372
JBrowse link
G ARMC12 armadillo repeat containing 12 increases expression EXP masitinib results in increased expression of ARMC12 mRNA CTD PMID:22747577 NCBI chr12:4,868,831...4,879,801
Ensembl chr12:4,869,774...4,879,793
JBrowse link
G ASCC1 activating signal cointegrator 1 complex subunit 1 decreases expression EXP masitinib results in decreased expression of ASCC1 mRNA CTD PMID:22747577 NCBI chr 4:22,779,644...22,876,434
Ensembl chr 4:22,779,781...22,874,215
JBrowse link
G B4GALT7 beta-1,4-galactosyltransferase 7 increases expression EXP masitinib results in increased expression of B4GALT7 mRNA CTD PMID:22747577 NCBI chr11:3,497,860...3,507,513
Ensembl chr11:3,498,153...3,505,034
JBrowse link
G BIRC5 baculoviral IAP repeat containing 5 decreases expression EXP masitinib results in decreased expression of BIRC5 mRNA CTD PMID:22747577 NCBI chr 9:2,930,308...2,959,307 JBrowse link
G BTBD3 BTB domain containing 3 decreases expression EXP masitinib results in decreased expression of BTBD3 mRNA CTD PMID:22747577 NCBI chr24:10,478,635...10,512,773
Ensembl chr24:10,479,900...10,512,185
JBrowse link
G CA2 carbonic anhydrase 2 decreases expression EXP masitinib results in decreased expression of CA2 mRNA CTD PMID:22747577 NCBI chr29:31,959,225...31,975,309
Ensembl chr29:31,935,172...31,980,579
JBrowse link
G CAMK2G calcium/calmodulin dependent protein kinase II gamma increases expression EXP masitinib results in increased expression of CAMK2G mRNA CTD PMID:22747577 NCBI chr 4:24,244,063...24,299,362
Ensembl chr 4:24,245,960...24,299,357
JBrowse link
G CAPG capping actin protein, gelsolin like increases expression EXP masitinib results in increased expression of CAPG protein CTD PMID:22747577 NCBI chr17:39,619,429...39,640,944
Ensembl chr17:39,619,248...39,640,942
JBrowse link
G CCT2 chaperonin containing TCP1 subunit 2 decreases expression EXP masitinib results in decreased expression of CCT2 protein CTD PMID:22747577 NCBI chr10:11,560,287...11,586,559
Ensembl chr10:11,560,396...11,578,433
JBrowse link
G CD5L CD5 molecule like increases expression EXP masitinib results in increased expression of CD5L mRNA CTD PMID:22747577 NCBI chr 7:40,516,190...40,526,528
Ensembl chr 7:40,516,190...40,526,528
JBrowse link
G CDADC1 cytidine and dCMP deaminase domain containing 1 increases expression EXP masitinib results in increased expression of CDADC1 mRNA CTD PMID:22747577 NCBI chr22:2,443,459...2,489,147
Ensembl chr22:2,436,206...2,489,016
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A increases expression EXP masitinib results in increased expression of CDKN1A mRNA CTD PMID:22747577 NCBI chr12:5,746,898...5,755,103
Ensembl chr12:5,745,852...5,892,281
JBrowse link
G CIAPIN1 cytokine induced apoptosis inhibitor 1 decreases expression EXP masitinib results in decreased expression of CIAPIN1 mRNA CTD PMID:22747577 NCBI chr 2:58,977,592...58,992,785
Ensembl chr 2:58,977,676...58,992,581
JBrowse link
G CIRBP cold inducible RNA binding protein increases expression EXP masitinib results in increased expression of CIRBP mRNA CTD PMID:22747577 NCBI chr20:57,521,609...57,526,526
Ensembl chr20:57,519,119...57,526,435
JBrowse link
G CLEC2B C-type lectin domain family 2 member B decreases expression EXP masitinib results in decreased expression of CLEC2B mRNA CTD PMID:22747577 NCBI chr27:36,088,754...36,143,581
Ensembl chr27:36,120,134...36,143,040
JBrowse link
G CMTM7 CKLF like MARVEL transmembrane domain containing 7 increases expression EXP masitinib results in increased expression of CMTM7 mRNA CTD PMID:22747577 NCBI chr23:12,317,636...12,382,836
Ensembl chr23:12,328,303...12,382,837
JBrowse link
G CORO1A coronin 1A increases expression EXP masitinib results in increased expression of CORO1A protein CTD PMID:22747577 NCBI chr 6:18,161,850...18,167,915
Ensembl chr 6:18,160,601...18,167,818
JBrowse link
G CPNE1 copine 1 increases expression EXP masitinib results in increased expression of CPNE1 mRNA CTD PMID:22747577 NCBI chr24:24,554,636...24,589,748
Ensembl chr24:24,554,636...24,589,731
JBrowse link
G CPNE6 copine 6 increases expression EXP masitinib results in increased expression of DHRS4 mRNA CTD PMID:22747577 NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
JBrowse link
G CTSK cathepsin K increases expression EXP masitinib results in increased expression of CTSK mRNA CTD PMID:22747577 NCBI chr17:59,928,725...59,938,293
Ensembl chr17:59,929,287...59,938,507
JBrowse link
G DLA-12 MHC class I DLA-12 increases expression EXP masitinib results in increased expression of DLA-12 mRNA CTD PMID:22747577 NCBI chr12:933,321...936,671
Ensembl chr12:932,613...987,561
JBrowse link
G DLA-64 MHC class I DLA-64 increases expression EXP masitinib results in increased expression of DLA-64 mRNA CTD PMID:22747577 NCBI chr12:983,573...986,969 JBrowse link
G DLGAP1 DLG associated protein 1 decreases expression EXP masitinib results in decreased expression of DLGAP1 mRNA CTD PMID:22747577 NCBI chr 7:70,082,563...70,949,116
Ensembl chr 7:70,081,885...70,406,213
JBrowse link
G DLGAP5 DLG associated protein 5 decreases expression EXP masitinib results in decreased expression of DLGAP5 mRNA CTD PMID:22747577 NCBI chr 8:30,998,806...31,038,614
Ensembl chr 8:30,994,402...31,036,540
JBrowse link
G DPCD deleted in primary ciliary dyskinesia homolog decreases expression EXP masitinib results in decreased expression of DPCD mRNA CTD PMID:22747577 NCBI chr28:14,201,302...14,219,121
Ensembl chr28:14,201,351...14,219,121
JBrowse link
G DPYSL3 dihydropyrimidinase like 3 decreases expression EXP masitinib results in decreased expression of DPYSL3 mRNA CTD PMID:22747577 NCBI chr 2:41,687,725...41,809,402
Ensembl chr 2:41,690,845...41,802,376
JBrowse link
G EBPL EBP like increases expression EXP masitinib results in increased expression of EBPL mRNA CTD PMID:22747577 NCBI chr22:2,116,588...2,137,935
Ensembl chr22:2,116,131...2,182,633
JBrowse link
G EDEM2 ER degradation enhancing alpha-mannosidase like protein 2 increases expression EXP masitinib results in increased expression of EDEM2 mRNA CTD PMID:22747577 NCBI chr24:24,137,228...24,165,995
Ensembl chr24:24,137,228...24,165,968
JBrowse link
G EIF3A eukaryotic translation initiation factor 3 subunit A decreases expression EXP masitinib results in decreased expression of EIF3A protein CTD PMID:22747577 NCBI chr28:29,290,668...29,326,851
Ensembl chr28:29,291,422...29,326,701
JBrowse link
G EIF4A1 eukaryotic translation initiation factor 4A1 decreases expression EXP masitinib results in decreased expression of EIF4A1 protein CTD PMID:22747577 NCBI chr 5:32,495,606...32,500,805
Ensembl chr 5:32,484,572...32,500,805
JBrowse link
G EIF5A2 eukaryotic translation initiation factor 5A2 decreases expression EXP masitinib results in decreased expression of EIF5A2 mRNA CTD PMID:22747577 NCBI chr34:35,309,812...35,322,382
Ensembl chr34:35,314,172...35,322,392
JBrowse link
G ELSPBP1 epididymal sperm binding protein 1 increases expression EXP masitinib results in increased expression of ELSPBP1 mRNA CTD PMID:22747577 NCBI chr 1:108,159,609...108,187,224
Ensembl chr 1:108,159,611...108,188,076
JBrowse link
G ETFDH electron transfer flavoprotein dehydrogenase decreases expression EXP masitinib results in decreased expression of ETFDH mRNA CTD PMID:22747577 NCBI chr15:55,752,170...55,781,118
Ensembl chr15:55,752,200...55,792,105
JBrowse link
G GGT1 gamma-glutamyltransferase 1 increases expression EXP masitinib results in increased expression of GGT1 mRNA CTD PMID:22747577 NCBI chr26:28,301,455...28,315,029 JBrowse link
G GKN1 gastrokine 1 increases expression EXP masitinib results in increased expression of GKN1 mRNA CTD PMID:22747577 NCBI chr10:67,788,329...67,793,445
Ensembl chr10:67,788,110...67,793,589
JBrowse link
G GMFB glia maturation factor beta decreases expression EXP masitinib results in decreased expression of GMFB mRNA CTD PMID:22747577 NCBI chr 8:30,394,020...30,408,408
Ensembl chr 8:30,359,499...30,408,357
JBrowse link
G GSTA4 glutathione S-transferase alpha 4 increases expression EXP masitinib results in increased expression of GSTA4 mRNA CTD PMID:22747577 NCBI chr12:20,426,724...20,443,200
Ensembl chr12:20,426,726...20,443,200
JBrowse link
G GXYLT1 glucoside xylosyltransferase 1 decreases expression EXP masitinib results in decreased expression of GXYLT1 mRNA CTD PMID:22747577 NCBI chr27:11,754,609...11,810,245
Ensembl chr27:11,765,072...11,807,787
JBrowse link
G HEBP2 heme binding protein 2 decreases expression EXP masitinib results in decreased expression of HEBP2 mRNA CTD PMID:22747577 NCBI chr 1:30,716,395...30,724,814
Ensembl chr 1:30,716,606...30,724,613
JBrowse link
G HERPUD1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression EXP masitinib results in increased expression of HERPUD1 mRNA CTD PMID:22747577 NCBI chr 2:59,388,492...59,400,028
Ensembl chr 2:59,388,494...59,400,003
JBrowse link
G HSP90B1 heat shock protein 90 beta family member 1 increases expression EXP masitinib results in increased expression of HSP90B1 protein CTD PMID:22747577 NCBI chr15:42,456,793...42,474,122
Ensembl chr15:42,456,764...42,579,311
JBrowse link
G HTR2B 5-hydroxytryptamine receptor 2B increases expression EXP masitinib results in increased expression of HTR2B mRNA CTD PMID:22747577 NCBI chr25:43,042,306...43,056,361
Ensembl chr25:43,042,173...43,056,612
JBrowse link
G HYAL3 hyaluronidase 3 increases expression EXP masitinib results in increased expression of HYAL3 mRNA CTD PMID:22747577 NCBI chr20:39,041,940...39,047,388
Ensembl chr20:39,042,070...39,047,365
JBrowse link
G IGFBP7 insulin like growth factor binding protein 7 increases expression EXP masitinib results in increased expression of IGFBP7 mRNA CTD PMID:22747577 NCBI chr13:49,138,406...49,207,235
Ensembl chr13:49,138,402...49,207,394
JBrowse link
G IL13 interleukin 13 increases expression EXP masitinib results in increased expression of IL13 mRNA CTD PMID:22747577 NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388
JBrowse link
G IMMP2L inner mitochondrial membrane peptidase subunit 2 increases expression EXP masitinib results in increased expression of IMMP2L mRNA CTD PMID:22747577 NCBI chr14:50,487,679...51,336,906 JBrowse link
G IRX6 iroquois homeobox 6 increases expression EXP masitinib results in increased expression of IRX6 protein CTD PMID:22747577 NCBI chr 2:60,630,688...60,636,285
Ensembl chr 2:60,630,447...60,636,416
JBrowse link
G ITGA6 integrin subunit alpha 6 decreases expression EXP masitinib results in decreased expression of ITGA6 mRNA CTD PMID:22747577 NCBI chr36:16,777,363...16,858,725
Ensembl chr36:16,776,863...16,855,449
JBrowse link
G JAML junction adhesion molecule like decreases expression EXP masitinib results in decreased expression of JAML mRNA CTD PMID:22747577 NCBI chr 5:15,485,378...15,513,457
Ensembl chr 5:15,476,582...15,513,075
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit increases expression EXP masitinib results in increased expression of JUN mRNA CTD PMID:22747577 NCBI chr 5:50,966,698...50,968,939 JBrowse link
G KCTD19 potassium channel tetramerization domain containing 19 increases expression EXP masitinib results in increased expression of KCTD19 mRNA CTD PMID:22747577 NCBI chr 5:82,060,946...82,093,248
Ensembl chr 5:82,061,449...82,093,246
JBrowse link
G KLHL5 kelch like family member 5 increases expression EXP masitinib results in increased expression of KLHL5 mRNA CTD PMID:22747577 NCBI chr 3:73,258,925...73,347,262
Ensembl chr 3:73,262,895...73,344,879
JBrowse link
G LBX2 ladybird homeobox 2 increases expression EXP masitinib results in increased expression of LBX2 mRNA CTD PMID:22747577 NCBI chr17:48,641,630...48,643,411
Ensembl chr17:48,641,674...48,643,239
JBrowse link
G LIN7C lin-7 homolog C, crumbs cell polarity complex component decreases expression EXP masitinib results in decreased expression of LIN7C mRNA CTD PMID:22747577 NCBI chr21:48,061,446...48,071,458
Ensembl chr21:48,064,929...48,071,429
JBrowse link
G LOC474850 heat shock 70 kDa protein 1-like increases expression EXP masitinib results in increased expression of HSPA1L mRNA CTD PMID:22747577 NCBI chr12:1,281,164...1,285,010
Ensembl chr12:1,281,472...1,285,440
JBrowse link
G LOC475707 GPN-loop GTPase 1 decreases expression EXP masitinib results in decreased expression of GPN1 mRNA CTD PMID:22747577 NCBI chr17:21,654,516...21,678,435
Ensembl chr17:21,545,673...21,673,157
JBrowse link
G LOC478000 phytanoyl-CoA hydroxylase-like increases expression EXP masitinib results in increased expression of PHYH mRNA CTD PMID:22747577 NCBI chr 2:23,185,901...23,206,719
Ensembl chr 2:23,185,782...23,253,497
JBrowse link
G LOC485255 hemoglobin subunit epsilon-2 increases expression EXP masitinib results in increased expression of HBG1 mRNA CTD PMID:22747577 NCBI chr21:28,193,163...28,194,746 JBrowse link
G LONRF1 LON peptidase N-terminal domain and ring finger 1 increases expression EXP masitinib results in increased expression of LONRF1 mRNA CTD PMID:22747577 NCBI chr16:36,220,324...36,256,896
Ensembl chr16:36,221,156...36,256,897
JBrowse link
G LRP1 LDL receptor related protein 1 increases expression EXP masitinib results in increased expression of LRP1 mRNA CTD PMID:22747577 NCBI chr10:1,260,256...1,341,705
Ensembl chr10:1,260,719...1,352,271
JBrowse link
G LRP8 LDL receptor related protein 8 decreases expression EXP masitinib results in decreased expression of LRP8 mRNA CTD PMID:22747577 NCBI chr 5:55,604,878...55,684,666
Ensembl chr 5:55,604,878...55,699,736
JBrowse link
G LYRM1 LYR motif containing 1 increases expression EXP masitinib results in increased expression of LYRM1 mRNA CTD PMID:22747577 NCBI chr 6:24,428,461...24,460,291
Ensembl chr 6:24,441,307...24,460,331
JBrowse link
G MAGEF1 MAGE family member F1 decreases expression EXP masitinib results in decreased expression of MAGEF1 mRNA CTD PMID:22747577 NCBI chr34:17,543,381...17,545,089
Ensembl chr34:17,543,906...17,544,868
JBrowse link
G MOB1B MOB kinase activator 1B decreases expression EXP masitinib results in decreased expression of MOB1B mRNA CTD PMID:22747577 NCBI chr13:60,145,168...60,197,916
Ensembl chr13:60,145,366...60,195,463
JBrowse link
G MPDZ multiple PDZ domain crumbs cell polarity complex component increases expression EXP masitinib results in increased expression of MPDZ mRNA CTD PMID:22747577 NCBI chr11:33,691,434...33,826,500
Ensembl chr11:33,692,296...33,826,437
JBrowse link
G MYOZ1 myozenin 1 increases expression EXP masitinib results in increased expression of MYOZ1 mRNA CTD PMID:22747577 NCBI chr 4:24,158,532...24,165,416
Ensembl chr 4:24,158,720...24,165,392
JBrowse link
G NAPG NSF attachment protein gamma decreases expression EXP masitinib results in decreased expression of NAPG mRNA CTD PMID:22747577 NCBI chr 7:76,403,561...76,424,994
Ensembl chr 7:76,403,595...76,423,170
JBrowse link
G NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1 decreases expression EXP masitinib results in decreased expression of NDUFS1 mRNA CTD PMID:22747577 NCBI chr37:14,680,908...14,713,838
Ensembl chr37:14,683,083...14,713,754
JBrowse link
G NFKBIA NFKB inhibitor alpha increases expression EXP masitinib results in increased expression of NFKBIA mRNA CTD PMID:22747577 NCBI chr 8:14,100,203...14,103,453
Ensembl chr 8:14,100,671...14,103,433
JBrowse link
G NRAS NRAS proto-oncogene, GTPase decreases expression EXP masitinib results in decreased expression of NRAS mRNA CTD PMID:22747577 NCBI chr17:52,411,733...52,418,788
Ensembl chr17:52,411,733...52,418,788
JBrowse link
G NSG1 neuronal vesicle trafficking associated 1 decreases expression EXP masitinib results in decreased expression of NSG1 mRNA CTD PMID:22747577 NCBI chr 3:69,805,646...69,831,200
Ensembl chr 3:69,805,592...69,831,194
JBrowse link
G NTRK1 neurotrophic receptor tyrosine kinase 1 increases expression EXP masitinib results in increased expression of NTRK1 mRNA CTD PMID:22747577 NCBI chr 7:41,140,931...41,159,326
Ensembl chr 7:41,140,879...41,159,288
JBrowse link
G OCA2 OCA2 melanosomal transmembrane protein decreases expression EXP masitinib results in decreased expression of OCA2 mRNA CTD PMID:22747577 NCBI chr 3:32,361,825...32,713,631
Ensembl chr 3:32,361,517...32,713,572
JBrowse link
G OGT O-linked N-acetylglucosamine (GlcNAc) transferase increases expression EXP masitinib results in increased expression of OGT mRNA CTD PMID:22747577 NCBI chr  X:55,821,227...55,857,597
Ensembl chr  X:55,821,234...55,855,502
JBrowse link
G OXCT1 3-oxoacid CoA-transferase 1 increases expression EXP masitinib results in increased expression of OXCT1 protein CTD PMID:22747577 NCBI chr 4:67,709,846...67,841,737
Ensembl chr 4:67,527,531...67,841,518
JBrowse link
G PARP14 poly(ADP-ribose) polymerase family member 14 increases expression EXP masitinib results in increased expression of PARP14 mRNA CTD PMID:22747577 NCBI chr33:25,763,282...25,798,284
Ensembl chr33:25,763,255...25,798,198
JBrowse link
G PCM1 pericentriolar material 1 increases expression EXP masitinib results in increased expression of PCM1 mRNA CTD PMID:22747577 NCBI chr16:41,212,733...41,291,654
Ensembl chr16:41,214,417...41,291,376
JBrowse link
G PCOLCE2 procollagen C-endopeptidase enhancer 2 decreases expression EXP masitinib results in decreased expression of PCOLCE2 mRNA CTD PMID:22747577 NCBI chr23:38,424,408...38,486,800
Ensembl chr23:38,426,216...38,487,252
JBrowse link
G PDE6H phosphodiesterase 6H increases expression EXP masitinib results in increased expression of PDE6H mRNA CTD PMID:22747577 NCBI chr27:31,640,731...31,664,494
Ensembl chr27:31,640,737...31,664,401
JBrowse link
G PDHA1 pyruvate dehydrogenase E1 subunit alpha 1 decreases expression EXP masitinib results in decreased expression of PDHA1 mRNA CTD PMID:22747577 NCBI chr  X:15,338,364...15,354,011
Ensembl chr  X:15,338,202...15,387,458
JBrowse link
G PDIA3 protein disulfide isomerase family A member 3 increases expression EXP masitinib results in increased expression of PDIA3 protein CTD PMID:22747577 NCBI chr30:10,487,926...10,513,437
Ensembl chr30:10,487,921...10,513,397
JBrowse link
G PEBP4 phosphatidylethanolamine binding protein 4 increases expression EXP masitinib results in increased expression of PEBP4 mRNA CTD PMID:22747577 NCBI chr25:34,329,160...34,574,086
Ensembl chr25:34,317,421...34,574,066
JBrowse link
G PECAM1 platelet and endothelial cell adhesion molecule 1 increases expression EXP masitinib results in increased expression of PECAM1 mRNA CTD PMID:22747577 NCBI chr 9:12,166,124...12,219,553
Ensembl chr 9:12,166,775...12,219,778
JBrowse link
G PHF10 PHD finger protein 10 increases expression EXP masitinib results in increased expression of PHF10 mRNA CTD PMID:22747577 NCBI chr12:71,955,354...71,998,283
Ensembl chr12:71,787,082...71,998,243
JBrowse link
G POMT1 protein O-mannosyltransferase 1 decreases expression EXP masitinib results in decreased expression of POMT1 mRNA CTD PMID:22747577 NCBI chr 9:52,615,349...52,631,538
Ensembl chr 9:52,615,655...52,630,836
JBrowse link
G POR cytochrome p450 oxidoreductase increases expression EXP masitinib results in increased expression of POR mRNA CTD PMID:22747577 NCBI chr 6:7,247,780...7,316,282
Ensembl chr 6:7,263,574...7,316,297
JBrowse link
G PPA1 inorganic pyrophosphatase 1 decreases expression EXP masitinib results in decreased expression of PPA1 protein CTD PMID:22747577 NCBI chr 4:21,145,547...21,189,985
Ensembl chr 4:21,145,547...21,182,748
JBrowse link
G PRPS2 phosphoribosyl pyrophosphate synthetase 2 decreases expression EXP masitinib results in decreased expression of PRPS2 mRNA CTD PMID:22747577 NCBI chr  X:9,281,686...9,326,551
Ensembl chr  X:9,281,730...9,418,289
JBrowse link
G PSMB9 proteasome 20S subunit beta 9 increases expression EXP masitinib results in increased expression of PSMB9 mRNA CTD PMID:22747577 NCBI chr12:2,432,287...2,438,920
Ensembl chr12:2,432,505...2,438,069
JBrowse link
G PSMD6 proteasome 26S subunit, non-ATPase 6 decreases expression EXP masitinib results in decreased expression of PSMD6 protein CTD PMID:22747577 NCBI chr20:27,206,801...27,220,059 JBrowse link
G PSMD9 proteasome 26S subunit, non-ATPase 9 decreases expression EXP masitinib results in decreased expression of PSMD9 mRNA CTD PMID:22747577 NCBI chr26:7,376,154...7,400,655
Ensembl chr26:7,377,413...7,400,573
JBrowse link
G PTH parathyroid hormone increases expression EXP masitinib results in increased expression of PTH mRNA CTD PMID:22747577 NCBI chr21:36,417,062...36,419,967
Ensembl chr21:36,417,058...36,419,967
JBrowse link
G PXYLP1 2-phosphoxylose phosphatase 1 decreases expression EXP masitinib results in decreased expression of ACPL2 mRNA CTD PMID:22747577 NCBI chr23:37,145,065...37,197,808
Ensembl chr23:37,145,086...37,196,427
JBrowse link
G R3HDM2 R3H domain containing 2 increases expression EXP masitinib results in increased expression of R3HDM2 mRNA CTD PMID:22747577 NCBI chr10:1,377,664...1,504,008
Ensembl chr10:1,370,350...1,504,017
JBrowse link
G RAB44 RAB44, member RAS oncogene family increases expression EXP masitinib results in increased expression of RAB44 mRNA CTD PMID:22747577 NCBI chr12:5,769,056...5,804,963
Ensembl chr12:5,770,882...5,804,949
JBrowse link
G RASGRP2 RAS guanyl releasing protein 2 increases expression EXP masitinib results in increased expression of RASGRP2 mRNA CTD PMID:22747577 NCBI chr18:52,412,331...52,426,910
Ensembl chr18:52,412,367...52,426,916
JBrowse link
G RCAN1 regulator of calcineurin 1 increases expression EXP masitinib results in increased expression of RCAN1 mRNA CTD PMID:22747577 NCBI chr31:29,908,046...30,002,412
Ensembl chr31:29,909,388...30,002,418
JBrowse link
G RGS13 regulator of G protein signaling 13 decreases expression EXP masitinib results in decreased expression of RGS13 mRNA CTD PMID:22747577 NCBI chr38:6,291,146...6,316,662
Ensembl chr38:6,291,182...6,315,198
JBrowse link
G SAR1A secretion associated Ras related GTPase 1A decreases expression EXP masitinib results in decreased expression of SAR1A mRNA CTD PMID:22747577 NCBI chr 4:21,120,788...21,136,409
Ensembl chr 4:21,123,028...21,136,973
JBrowse link
G SCD stearoyl-CoA desaturase decreases expression EXP masitinib results in decreased expression of SCD mRNA CTD PMID:22747577 NCBI chr28:13,112,741...13,129,129
Ensembl chr28:13,113,006...13,125,801
JBrowse link
G SELENBP1 selenium binding protein 1 increases expression EXP masitinib results in increased expression of SELENBP1 protein CTD PMID:22747577 NCBI chr17:60,410,727...60,418,770
Ensembl chr17:60,410,734...60,418,704
JBrowse link
G SERPINE2 serpin family E member 2 increases expression EXP masitinib results in increased expression of SERPINE2 mRNA CTD PMID:22747577 NCBI chr37:29,699,551...29,750,151
Ensembl chr37:29,700,024...29,724,228
JBrowse link
G SFT2D2 SFT2 domain containing 2 decreases expression EXP masitinib results in decreased expression of SFT2D2 mRNA CTD PMID:22747577 NCBI chr 7:30,258,748...30,281,371 JBrowse link
G SLA Src like adaptor increases expression EXP masitinib results in increased expression of SLA mRNA CTD PMID:22747577 NCBI chr13:29,503,304...29,590,679
Ensembl chr13:29,504,867...29,569,773
JBrowse link
G SLC25A12 solute carrier family 25 member 12 decreases expression EXP masitinib results in decreased expression of SLC25A12 mRNA CTD PMID:22747577 NCBI chr36:16,185,011...16,391,080
Ensembl chr36:16,185,649...16,483,016
JBrowse link
G SMC5 structural maintenance of chromosomes 5 decreases expression EXP masitinib results in decreased expression of SMC5 mRNA CTD PMID:22747577 NCBI chr 1:87,192,988...87,285,678
Ensembl chr 1:87,194,867...87,285,606
JBrowse link
G SRR serine racemase increases expression EXP masitinib results in increased expression of SRR mRNA CTD PMID:22747577
G STING1 stimulator of interferon response cGAMP interactor 1 increases expression EXP masitinib results in increased expression of TMEM173 mRNA CTD PMID:22747577 NCBI chr 2:34,783,947...34,792,204
Ensembl chr 2:34,784,232...34,789,072
JBrowse link
G STOX1 storkhead box 1 increases expression EXP masitinib results in increased expression of STOX1 mRNA CTD PMID:22747577 NCBI chr 4:20,013,893...20,065,480
Ensembl chr 4:20,014,007...20,060,394
JBrowse link
G STX16 syntaxin 16 increases expression EXP masitinib results in increased expression of STX16 mRNA CTD PMID:22747577 NCBI chr24:43,425,719...43,451,828
Ensembl chr24:43,426,470...43,449,077
JBrowse link
G STYXL1 serine/threonine/tyrosine interacting like 1 increases expression EXP masitinib results in increased expression of STYXL1 mRNA CTD PMID:22747577 NCBI chr 6:7,323,911...7,389,878
Ensembl chr 6:7,316,477...7,389,842
JBrowse link
G TARDBP TAR DNA binding protein decreases expression EXP masitinib results in decreased expression of TARDBP protein CTD PMID:22747577 NCBI chr 2:84,987,752...84,998,136
Ensembl chr 2:84,989,952...84,998,593
JBrowse link
G TBC1D14 TBC1 domain family member 14 decreases expression EXP masitinib results in decreased expression of TBC1D14 mRNA CTD PMID:22747577 NCBI chr 3:58,992,743...59,097,581
Ensembl chr 3:58,926,237...59,097,621
JBrowse link
G TCN2 transcobalamin 2 increases expression EXP masitinib results in increased expression of TCN2 mRNA CTD PMID:22747577 NCBI chr26:23,693,664...23,710,342
Ensembl chr26:23,693,773...23,709,832
JBrowse link
G TCP1 t-complex 1 decreases expression EXP masitinib results in decreased expression of TCP1 protein CTD PMID:22747577 NCBI chr 1:49,029,260...49,038,023
Ensembl chr 1:49,029,282...49,038,020
JBrowse link
G TEAD4 TEA domain transcription factor 4 increases expression EXP masitinib results in increased expression of TEAD4 mRNA CTD PMID:22747577 NCBI chr27:41,744,100...41,783,223
Ensembl chr27:41,748,871...41,803,556
JBrowse link
G THEMIS2 thymocyte selection associated family member 2 decreases expression EXP masitinib results in decreased expression of THEMIS2 mRNA CTD PMID:22747577 NCBI chr 2:72,465,719...72,501,962
Ensembl chr 2:72,464,026...72,502,928
JBrowse link
G TM2D2 TM2 domain containing 2 increases expression EXP masitinib results in increased expression of TM2D2 mRNA CTD PMID:22747577 NCBI chr16:26,551,563...26,557,554
Ensembl chr16:26,551,628...26,556,285
JBrowse link
G TMEM108 transmembrane protein 108 increases expression EXP masitinib results in increased expression of TMEM108 mRNA CTD PMID:22747577 NCBI chr23:29,992,038...30,331,791
Ensembl chr23:29,992,021...30,396,840
JBrowse link
G TMEM260 transmembrane protein 260 increases expression EXP masitinib results in increased expression of TMEM260 mRNA CTD PMID:22747577 NCBI chr 8:32,238,992...32,309,320
Ensembl chr 8:32,238,988...32,306,317
JBrowse link
G TNFSF10 TNF superfamily member 10 increases expression EXP masitinib results in increased expression of TNFSF10 mRNA CTD PMID:22747577 NCBI chr34:36,719,249...36,734,989
Ensembl chr34:36,670,849...36,735,060
JBrowse link
G TNPO1 transportin 1 decreases expression EXP masitinib results in decreased expression of TNPO1 mRNA CTD PMID:22747577 NCBI chr 2:55,795,737...55,859,366
Ensembl chr 2:55,799,907...55,851,213
JBrowse link
G TNS1 tensin 1 decreases expression EXP masitinib results in decreased expression of TNS1 mRNA CTD PMID:22747577 NCBI chr37:24,578,855...24,776,153
Ensembl chr37:24,581,806...24,808,049
JBrowse link
G TOX thymocyte selection associated high mobility group box increases expression EXP masitinib results in increased expression of TOX mRNA CTD PMID:22747577 NCBI chr29:9,542,471...9,841,759
Ensembl chr29:9,544,561...9,842,034
JBrowse link
G TSHB thyroid stimulating hormone subunit beta increases expression EXP masitinib results in increased expression of TSHB mRNA CTD PMID:22747577 NCBI chr17:52,659,137...52,685,388
Ensembl chr17:52,681,357...52,685,390
JBrowse link
G TSPAN2 tetraspanin 2 increases expression EXP masitinib results in increased expression of TSPAN2 mRNA CTD PMID:22747577 NCBI chr17:52,692,744...52,749,048
Ensembl chr17:52,694,603...52,744,276
JBrowse link
G TTC38 tetratricopeptide repeat domain 38 increases expression EXP masitinib results in increased expression of TTC38 protein CTD PMID:22747577 NCBI chr10:19,887,285...19,910,347
Ensembl chr10:19,773,373...19,910,683
JBrowse link
G TTLL1 TTL family tubulin polyglutamylase complex subunit L1 decreases expression EXP masitinib results in decreased expression of TTLL1 mRNA CTD PMID:22747577 NCBI chr10:22,456,150...22,492,375
Ensembl chr10:22,456,146...22,488,505
JBrowse link
G UCHL3 ubiquitin C-terminal hydrolase L3 increases expression EXP masitinib results in increased expression of UCHL3 protein CTD PMID:22747577 NCBI chr22:29,348,962...29,397,944
Ensembl chr22:29,348,706...29,407,965
JBrowse link
G UROD uroporphyrinogen decarboxylase increases expression EXP masitinib results in increased expression of UROD protein CTD PMID:22747577 NCBI chr15:15,313,808...15,317,130
Ensembl chr15:15,312,674...15,320,010
JBrowse link
G UROS uroporphyrinogen III synthase increases expression EXP masitinib results in increased expression of UROS mRNA CTD PMID:22747577 NCBI chr28:34,952,074...34,983,532
Ensembl chr28:34,948,003...34,983,532
JBrowse link
G VCPKMT valosin containing protein lysine methyltransferase decreases expression EXP masitinib results in decreased expression of VCPKMT mRNA CTD PMID:22747577 NCBI chr 8:26,611,333...26,636,700
Ensembl chr 8:26,625,677...26,636,316
JBrowse link
G WAPL WAPL cohesin release factor decreases expression EXP masitinib results in decreased expression of WAPAL mRNA CTD PMID:22747577 NCBI chr 4:34,219,644...34,297,456
Ensembl chr 4:34,219,645...34,302,839
JBrowse link
G YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta increases expression EXP masitinib results in increased expression of YWHAZ protein CTD PMID:22747577 NCBI chr13:2,729,404...2,764,422 JBrowse link
G ZNF23 zinc finger protein 23 increases expression EXP masitinib results in increased expression of ZNF23 mRNA CTD PMID:22747577 NCBI chr 5:77,246,374...77,260,761
Ensembl chr 5:77,246,667...77,260,350
JBrowse link
penconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A2 solute carrier family 22 member 2 decreases activity EXP penconazole results in decreased activity of SLC22A2 protein CTD PMID:36669674 NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
JBrowse link
G SLC22A5 solute carrier family 22 member 5 decreases activity EXP penconazole results in decreased activity of SLC22A5 protein CTD PMID:36669674 NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
JBrowse link
G SLC47A1 solute carrier family 47 member 1 decreases activity EXP penconazole results in decreased activity of SLC47A1 protein CTD PMID:36669674 NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
JBrowse link
G SLC47A2 solute carrier family 47 member 2 decreases activity EXP penconazole results in decreased activity of SLC47A2 protein CTD PMID:36669674 NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
JBrowse link
pindolol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G REN renin multiple interactions EXP Pindolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] CTD PMID:6103674 NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
JBrowse link
prochloraz term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AHR aryl hydrocarbon receptor multiple interactions EXP [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz CTD PMID:24389113 NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
JBrowse link
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 multiple interactions EXP [prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein CTD PMID:24389113 NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
JBrowse link
quinacrine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HEXB hexosaminidase subunit beta multiple interactions EXP Quinacrine promotes the reaction [mastoparan results in increased secretion of HEXB protein] CTD PMID:21671308 NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
JBrowse link
ritonavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB1 ATP binding cassette subfamily B member 1 multiple interactions EXP allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] CTD PMID:15266218 NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
JBrowse link
G NR1I2 nuclear receptor subfamily 1 group I member 2 increases activity EXP Ritonavir results in increased activity of NR1I2 protein CTD PMID:27732639 NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
JBrowse link
serotonin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen increases response to substance
multiple interactions
EXP AGT protein modified form results in increased susceptibility to Serotonin
Deferoxamine inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin]; Reactive Oxygen Species inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin]
CTD PMID:8021468 NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
JBrowse link
G EDN1 endothelin 1 increases activity EXP Serotonin results in increased activity of EDN1 protein CTD PMID:9918753 NCBI chr35:11,808,892...11,815,383
Ensembl chr35:11,808,892...11,815,383
JBrowse link
silodosin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ADRA1A adrenoceptor alpha 1A multiple interactions EXP silodosin binds to and results in decreased activity of ADRA1A protein; silodosin inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein] CTD PMID:19371927 NCBI chr25:30,690,959...30,801,484
Ensembl chr25:30,693,571...30,801,486
JBrowse link
SR 144528 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CNR2 cannabinoid receptor 2 multiple interactions EXP SR 144528 binds to and results in decreased activity of CNR2 protein CTD PMID:21871882 NCBI chr 2:75,640,636...75,662,000
Ensembl chr 2:75,658,999...75,660,126
JBrowse link
tebuconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A2 solute carrier family 22 member 2 decreases activity EXP tebuconazole results in decreased activity of SLC22A2 protein CTD PMID:36669674 NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
JBrowse link
G SLC22A5 solute carrier family 22 member 5 decreases activity EXP tebuconazole results in decreased activity of SLC22A5 protein CTD PMID:36669674 NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
JBrowse link
G SLC47A1 solute carrier family 47 member 1 decreases activity EXP tebuconazole results in decreased activity of SLC47A1 protein CTD PMID:36669674 NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
JBrowse link
G SLC47A2 solute carrier family 47 member 2 decreases activity EXP tebuconazole results in decreased activity of SLC47A2 protein CTD PMID:36669674 NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
JBrowse link
triazoles term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NR1I3 nuclear receptor subfamily 1 group I member 3 increases activity EXP Triazoles results in increased activity of NR1I3 protein alternative form CTD PMID:21778469 NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
JBrowse link
triticonazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A5 solute carrier family 22 member 5 decreases activity EXP triticonazole results in decreased activity of SLC22A5 protein CTD PMID:36669674 NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
JBrowse link
G SLC47A1 solute carrier family 47 member 1 decreases activity EXP triticonazole results in decreased activity of SLC47A1 protein CTD PMID:36669674 NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
JBrowse link
tunicamycin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSP90B1 heat shock protein 90 beta family member 1 increases expression EXP Tunicamycin results in increased expression of HSP90B1 protein CTD PMID:17416481 NCBI chr15:42,456,793...42,474,122
Ensembl chr15:42,456,764...42,579,311
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP Tunicamycin results in increased expression of HSPA5 protein CTD PMID:17416481 NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
JBrowse link
uniconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G SLC22A5 solute carrier family 22 member 5 decreases activity EXP uniconazole results in decreased activity of SLC22A5 protein CTD PMID:36669674 NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
JBrowse link
G SLC47A1 solute carrier family 47 member 1 decreases activity EXP uniconazole results in decreased activity of SLC47A1 protein CTD PMID:36669674 NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
JBrowse link
UTP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G P2RY2 purinergic receptor P2Y2 multiple interactions
increases activity
EXP [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid; [Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] CTD PMID:10604969 NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 495
    chemical entity 495
      molecular entity 495
        polyatomic entity 488
          molecule 467
            cyclic compound 448
              organic cyclic compound 448
                organic heterocyclic compound 410
                  heteroarene 196
                    (-)-Ngaione 0
                    (2-Furanylmethyl) methyl disulfide 0
                    (2R,3S,4R,4aR,7R,8S)-8-[2-(furan-3-yl)ethyl]-4a,7,8-trimethylspiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxirane]-2,3-diol 0
                    (5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone 0
                    (E)-1-(furan-2-yl)-N-(2-methylbutyl)methanimine 0
                    (E)-1-(furan-2-yl)-N-isobutylmethanimine 0
                    (E)-1-(furan-2-yl)-N-isopentylmethanimine 0
                    (E)-6-Methyl-6-(5-methyl-2-furanyl)-3-hepten-2-one 0
                    1,4-Ipomeadiol 0
                    1-(2-Furanyl)-2-propanone 0
                    1-(2-Furyl)butan-3-one 0
                    1-(3-hydroxy-2,4,4-trimethyl-1-oxido-5-thiophen-2-yl-2-imidazol-1-iumyl)ethanone 0
                    1-(6-methyl-2-pyridinyl)-N-(3-pyridinyl)-4-imidazolecarboxamide 0
                    1-Ipomeanol 0
                    1-adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester 0
                    1-azocanyl-[(2R,4R)-2-(4-hydroxybutoxy)-4-thiophen-2-yl-3,4-dihydro-2H-pyran-6-yl]methanone 0
                    12,13-Dimethyl-5,14-dioxabicyclo[9.2.1]-tetradeca-1(13),11-dien-4-one 0
                    2,3,5-Trimethylfuran 0
                    2,4-Difurfurylfuran 0
                    2,5-Dimethyl-3-(methyldithio)furan 0
                    2,5-bis(hydroxymethyl)furan monoacetate 0
                    2-(1-Pentenyl)furan 0
                    2-(12-Tridecyn-1-yl)furan 0
                    2-(2-Furanyl)-3-methyl-2-butenal 0
                    2-(2-Thienyl)ethanol 0
                    2-(2-Thienyl)furan 0
                    2-(2-Thienylsulfonyl)acetonitrile 0
                    2-(2-Thienylsulfonyl)ethanethioamide 0
                    2-(2-furanyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b][1,3]oxazin-4-one 0
                    2-(2-thienylmethylidene)hydrazine-1-carboxamide 0
                    2-(D-glycerol-1,2-dihydroxyethyl)furan 0
                    2-(Ethoxymethyl)furan 0
                    2-(Methoxymethyl)furan 0
                    2-(N-vinylacetamide)-4-hydroxymethyl-3-ene-butyrolactone 0
                    2-(Propan-2-yl)furan 0
                    2-Ethyl-4-(2-furanyl)-2-propenal 0
                    2-Ethynylthiophene 0
                    2-Furanmethanethiol 0
                    2-Furanylmethyl propanoate 0
                    2-Heptadecylfuran 0
                    2-Hexylthiophene 0
                    2-Isopropyl-5-methylfuran 0
                    2-Methyl-3-(propyldithio)furan 0
                    2-Methyl-3-furanthiol 0
                    2-Pentadecylfuran 0
                    2-Propylfuran 0
                    2-Thiopheneacrylic acid 0
                    2-[(2R,4aR,12aR)-5-methyl-8-[[(5-methyl-3-isoxazolyl)-oxomethyl]amino]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]acetic acid 0
                    2-[(Isopropylthio)methyl]furan 0
                    2-amino-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]thiazin-4-one 0
                    2-furanacetic acid 0
                    2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone 0
                    2-sulfanylidene-1,3-dithiole-4,5-dicarboxylic acid dimethyl ester 0
                    3,4-Diethylthiophene 0
                    3,4-Dihydro-5-(5-methyl-2-furanyl)-2H-pyrrole 0
                    3-(2-Fluoropropyl)thiophene 0
                    3-(2-Furanyl)-2-propenal 0
                    3-(2-Furanylmethylene)pyrrolidine 0
                    3-(3-Furanyl)-2-methyl-2-propenal 0
                    3-(4-Methyl-3-pentenyl)thiophene 0
                    3-(5-Methyl-2-furanyl)butanal 0
                    3-(5-Methyl-2-furyl)prop-2-enal 0
                    3-Ethylfuran 0
                    3-Thiophenemethanol 0
                    3-acetylamino-N-2-thienylpropanamide 0
                    4,6-dioxo-1H-1,3,5-triazine-2-carboxamide 0
                    4-(2-Furanyl)-3-buten-2-one 0
                    4-(2-Furanylmethylene)-3,4-dihydro-2H-pyrrole 0
                    4-(2-furanylmethylidene)-2-methyl-5-oxo-1-prop-2-enyl-3-pyrrolecarboxylic acid methyl ester 0
                    4-(5-methyl-2-furanyl)-2-butanone 0
                    4-[(2-Furanylmethyl)thio]-2-pentanone 0
                    4-[(E)-[hydroxymethyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide 0
                    4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide 0
                    4-[oxo-(pyridin-4-ylamino)methyl]-1H-imidazole-5-carboxylic acid ethyl ester 0
                    4-acetyl-N-[4-(4-chlorophenyl)-2-thiazolyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide 0
                    4-bromo-1-methyl-N-(2-thiazolyl)-3-pyrazolecarboxamide 0
                    4-chloro-1-methyl-N-[1-[(4-methylphenyl)methyl]-3-pyrazolyl]-3-pyrazolecarboxamide 0
                    4-chloro-N-[(4-chlorophenyl)methyl]-3-nitro-1H-pyrazole-5-carboxamide 0
                    4-methyl-2-(3-methyl-2-butenyl)-furan 0
                    5-(2-Furanyl)-3,4-dihydro-2H-pyrrole 0
                    5-(2-furanyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                    5-(2-hydroxyethyl)-2-furanacetic acid 0
                    5-(2-methylphenyl)-N-(phenylmethyl)-2-furancarboxamide 0
                    5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide 0
                    5-(3-hydroxyphenyl)-N-[2-(4-morpholinyl)ethyl]-3-isoxazolecarboxamide 0
                    5-(4-bromophenyl)-N,N-diethyl-3-isoxazolecarboxamide 0
                    5-(4-bromophenyl)-N-propan-2-yl-3-isoxazolecarboxamide 0
                    5-(4-chlorophenyl)-N-(2-furanylmethyl)-3-isoxazolecarboxamide 0
                    5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                    5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                    5-Methyl-2-(trifluoromethyl)-3-furamide 0
                    5-[(4-fluorophenyl)methylsulfonylmethyl]-N-(2-oxolanylmethyl)-2-furancarboxamide 0
                    5-[2H-Pyrrol-4-(3H)-ylidenemethyl]-2-furanmethanol 0
                    5-bromo-N-[1-(2,5-dimethylphenyl)ethyl]-2-furancarboxamide 0
                    5-bromo-N-[2-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]-2-furancarboxamide 0
                    5-bromo-N-[6-[[(5-bromo-2-furanyl)-oxomethyl]amino]-2-pyridinyl]-2-furancarboxamide 0
                    5-methyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                    5-methyl-N-(5-methyl-3-isoxazolyl)-3-isoxazolecarboxamide 0
                    5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide 0
                    5-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-isoxazolecarboxamide 0
                    5-phenyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                    6-Methyl-6-(5-methylfuran-2-yl)heptan-2-one 0
                    Amycolasporin E 0
                    Avocadenofuran 0
                    Avocadienofuran 0
                    BBT(OH)2 0
                    Bis(2,5-dimethyl-3-furanyl) disulfide 0
                    Bis(2-furanylmethyl) disulfide 0
                    Bis(2-methyl-3-furanyl)tetrasulfide 0
                    Brasilamide E 0
                    Camellimidazole D 0
                    Camellimidazole F 0
                    Di-2-furanylmethane 0
                    Diproximicin A 0
                    E-2-Methyl-5-(fur-3-yl)-pent-2-enal 0
                    Elsholtzidiol 0
                    Ethyl 3-[(2-furanylmethyl)thio]propanoate 0
                    Ethyl 3-thiopheneacetate 0
                    Furfuryl 2-methyl-3-furyl disulfide 0
                    Furfuryl acetate 0
                    Furfuryl propyl disulfide 0
                    Furfuryl thioacetate 0
                    Heptemerone C 0
                    Isoavocadienofuran 0
                    N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                    N-(2-adamantyl)-4-bromo-1-methyl-3-pyrazolecarboxamide 0
                    N-(2-cyano-1-cyclopentenyl)-1-ethyl-3-pyrazolecarboxamide 0
                    N-(2-furylmethyl)-N'-isobutylthiourea 0
                    N-(2-furylmethyl)thiourea 0
                    N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-2-furancarboxamide 0
                    N-(2-thienylmethyl)hydrazine-1-carbothioamide 0
                    N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide 0
                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(2-methylpropyl)-3-isoxazolecarboxamide 0
                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide 0
                    N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                    N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-3-isoxazolecarboxamide 0
                    N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                    N-(4-cyano-2-methyl-3-pyrazolyl)-5-(4-methylphenyl)-3-isoxazolecarboxamide 0
                    N-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-2-furancarboxamide 0
                    N-(5-chloro-2-pyridinyl)-2-ethyl-3-pyrazolecarboxamide 0
                    N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                    N-(6-tert-butyl-3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                    N-Cyclohexyl-5-(2-thienyl)-1,2-oxazole-3-carboxamide 0
                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(ethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-(propylamino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(2R,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[1-(2-furanyl)ethylideneamino]carbamic acid tert-butyl ester 0
                    N-[1-[(4-fluorophenyl)methyl]-3,5-dimethyl-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                    N-[1-[(4-fluorophenyl)methyl]-3-pyrazolyl]-5-methyl-2-furancarboxamide 0
                    N-[1-[(4-fluorophenyl)methyl]-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                    N-[2-(1-cyclohexenyl)ethyl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[4-(3,4-dimethylphenyl)-2-thiazolyl]-2-furancarboxamide 0
                    N-[4-(4-chlorophenyl)-2-thiazolyl]-N-[3-(diethylamino)propyl]-2-furancarboxamide 0
                    N-\{2-[(4-chlorobenzyl)thio]ethyl\}-2-furamide 0
                    N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                    N-cyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                    N-cyclopropyl-5-thiophen-2-yl-3-isoxazolecarboxamide 0
                    N-ethyl-2-Furancarboxamide 0
                    N-phenethyl-2-furamide 0
                    N1-(2-furylmethyl)-2-cyanoacetamide 0
                    Netropsin Dihydrochloride 0
                    Oxonol 0
                    PD 125375 0
                    Penicillilactone A 0
                    Phaeofuran A 0
                    Proximicin A 0
                    Proximicin F 0
                    Proximicin G 0
                    Pyrrole-2-carboxamide 0
                    S-(2-Furanylmethyl) methanethioate 0
                    S-(2-Furanylmethyl) propanethioate 0
                    TAN-868 A 0
                    Thiophene-2-thiol 0
                    Thiophene-3-carbothioamide 0
                    Trichocitrin 0
                    [4-[1-(1-cyclopentyl-5-tetrazolyl)propyl]-1-piperazinyl]-(2-furanyl)methanone 0
                    alpha-Methyl-2-furanacrolein 0
                    azaarene + 0
                    ethylmethylthiambutene 0
                    heteroaryl group + 0
                    hydracarbazine 0
                    imidazopyrimidine + 21
                    monocyclic heteroarene + 170
                    nucleobase-containing molecular entity + 5
                    penthienate 0
                    polycyclic heteroarene + 8
                    pteridines + 0
                    rufinamide 0
                    tetrapyrrole + 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 495
    subatomic particle 495
      composite particle 495
        hadron 495
          baryon 495
            nucleon 495
              atomic nucleus 495
                atom 495
                  main group element atom 488
                    p-block element atom 488
                      carbon group element atom 477
                        carbon atom 476
                          organic molecular entity 476
                            organic molecule 465
                              organic cyclic compound 448
                                organic heterocyclic compound 410
                                  heteroarene 196
                                    (-)-Ngaione 0
                                    (2-Furanylmethyl) methyl disulfide 0
                                    (2R,3S,4R,4aR,7R,8S)-8-[2-(furan-3-yl)ethyl]-4a,7,8-trimethylspiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxirane]-2,3-diol 0
                                    (5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone 0
                                    (E)-1-(furan-2-yl)-N-(2-methylbutyl)methanimine 0
                                    (E)-1-(furan-2-yl)-N-isobutylmethanimine 0
                                    (E)-1-(furan-2-yl)-N-isopentylmethanimine 0
                                    (E)-6-Methyl-6-(5-methyl-2-furanyl)-3-hepten-2-one 0
                                    1,4-Ipomeadiol 0
                                    1-(2-Furanyl)-2-propanone 0
                                    1-(2-Furyl)butan-3-one 0
                                    1-(3-hydroxy-2,4,4-trimethyl-1-oxido-5-thiophen-2-yl-2-imidazol-1-iumyl)ethanone 0
                                    1-(6-methyl-2-pyridinyl)-N-(3-pyridinyl)-4-imidazolecarboxamide 0
                                    1-Ipomeanol 0
                                    1-adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester 0
                                    1-azocanyl-[(2R,4R)-2-(4-hydroxybutoxy)-4-thiophen-2-yl-3,4-dihydro-2H-pyran-6-yl]methanone 0
                                    12,13-Dimethyl-5,14-dioxabicyclo[9.2.1]-tetradeca-1(13),11-dien-4-one 0
                                    2,3,5-Trimethylfuran 0
                                    2,4-Difurfurylfuran 0
                                    2,5-Dimethyl-3-(methyldithio)furan 0
                                    2,5-bis(hydroxymethyl)furan monoacetate 0
                                    2-(1-Pentenyl)furan 0
                                    2-(12-Tridecyn-1-yl)furan 0
                                    2-(2-Furanyl)-3-methyl-2-butenal 0
                                    2-(2-Thienyl)ethanol 0
                                    2-(2-Thienyl)furan 0
                                    2-(2-Thienylsulfonyl)acetonitrile 0
                                    2-(2-Thienylsulfonyl)ethanethioamide 0
                                    2-(2-furanyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b][1,3]oxazin-4-one 0
                                    2-(2-thienylmethylidene)hydrazine-1-carboxamide 0
                                    2-(D-glycerol-1,2-dihydroxyethyl)furan 0
                                    2-(Ethoxymethyl)furan 0
                                    2-(Methoxymethyl)furan 0
                                    2-(N-vinylacetamide)-4-hydroxymethyl-3-ene-butyrolactone 0
                                    2-(Propan-2-yl)furan 0
                                    2-Ethyl-4-(2-furanyl)-2-propenal 0
                                    2-Ethynylthiophene 0
                                    2-Furanmethanethiol 0
                                    2-Furanylmethyl propanoate 0
                                    2-Heptadecylfuran 0
                                    2-Hexylthiophene 0
                                    2-Isopropyl-5-methylfuran 0
                                    2-Methyl-3-(propyldithio)furan 0
                                    2-Methyl-3-furanthiol 0
                                    2-Pentadecylfuran 0
                                    2-Propylfuran 0
                                    2-Thiopheneacrylic acid 0
                                    2-[(2R,4aR,12aR)-5-methyl-8-[[(5-methyl-3-isoxazolyl)-oxomethyl]amino]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]acetic acid 0
                                    2-[(Isopropylthio)methyl]furan 0
                                    2-amino-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]thiazin-4-one 0
                                    2-furanacetic acid 0
                                    2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone 0
                                    2-sulfanylidene-1,3-dithiole-4,5-dicarboxylic acid dimethyl ester 0
                                    3,4-Diethylthiophene 0
                                    3,4-Dihydro-5-(5-methyl-2-furanyl)-2H-pyrrole 0
                                    3-(2-Fluoropropyl)thiophene 0
                                    3-(2-Furanyl)-2-propenal 0
                                    3-(2-Furanylmethylene)pyrrolidine 0
                                    3-(3-Furanyl)-2-methyl-2-propenal 0
                                    3-(4-Methyl-3-pentenyl)thiophene 0
                                    3-(5-Methyl-2-furanyl)butanal 0
                                    3-(5-Methyl-2-furyl)prop-2-enal 0
                                    3-Ethylfuran 0
                                    3-Thiophenemethanol 0
                                    3-acetylamino-N-2-thienylpropanamide 0
                                    4,6-dioxo-1H-1,3,5-triazine-2-carboxamide 0
                                    4-(2-Furanyl)-3-buten-2-one 0
                                    4-(2-Furanylmethylene)-3,4-dihydro-2H-pyrrole 0
                                    4-(2-furanylmethylidene)-2-methyl-5-oxo-1-prop-2-enyl-3-pyrrolecarboxylic acid methyl ester 0
                                    4-(5-methyl-2-furanyl)-2-butanone 0
                                    4-[(2-Furanylmethyl)thio]-2-pentanone 0
                                    4-[(E)-[hydroxymethyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide 0
                                    4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide 0
                                    4-[oxo-(pyridin-4-ylamino)methyl]-1H-imidazole-5-carboxylic acid ethyl ester 0
                                    4-acetyl-N-[4-(4-chlorophenyl)-2-thiazolyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide 0
                                    4-bromo-1-methyl-N-(2-thiazolyl)-3-pyrazolecarboxamide 0
                                    4-chloro-1-methyl-N-[1-[(4-methylphenyl)methyl]-3-pyrazolyl]-3-pyrazolecarboxamide 0
                                    4-chloro-N-[(4-chlorophenyl)methyl]-3-nitro-1H-pyrazole-5-carboxamide 0
                                    4-methyl-2-(3-methyl-2-butenyl)-furan 0
                                    5-(2-Furanyl)-3,4-dihydro-2H-pyrrole 0
                                    5-(2-furanyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                                    5-(2-hydroxyethyl)-2-furanacetic acid 0
                                    5-(2-methylphenyl)-N-(phenylmethyl)-2-furancarboxamide 0
                                    5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide 0
                                    5-(3-hydroxyphenyl)-N-[2-(4-morpholinyl)ethyl]-3-isoxazolecarboxamide 0
                                    5-(4-bromophenyl)-N,N-diethyl-3-isoxazolecarboxamide 0
                                    5-(4-bromophenyl)-N-propan-2-yl-3-isoxazolecarboxamide 0
                                    5-(4-chlorophenyl)-N-(2-furanylmethyl)-3-isoxazolecarboxamide 0
                                    5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                                    5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                                    5-Methyl-2-(trifluoromethyl)-3-furamide 0
                                    5-[(4-fluorophenyl)methylsulfonylmethyl]-N-(2-oxolanylmethyl)-2-furancarboxamide 0
                                    5-[2H-Pyrrol-4-(3H)-ylidenemethyl]-2-furanmethanol 0
                                    5-bromo-N-[1-(2,5-dimethylphenyl)ethyl]-2-furancarboxamide 0
                                    5-bromo-N-[2-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]-2-furancarboxamide 0
                                    5-bromo-N-[6-[[(5-bromo-2-furanyl)-oxomethyl]amino]-2-pyridinyl]-2-furancarboxamide 0
                                    5-methyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                                    5-methyl-N-(5-methyl-3-isoxazolyl)-3-isoxazolecarboxamide 0
                                    5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide 0
                                    5-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-isoxazolecarboxamide 0
                                    5-phenyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                                    6-Methyl-6-(5-methylfuran-2-yl)heptan-2-one 0
                                    Amycolasporin E 0
                                    Avocadenofuran 0
                                    Avocadienofuran 0
                                    BBT(OH)2 0
                                    Bis(2,5-dimethyl-3-furanyl) disulfide 0
                                    Bis(2-furanylmethyl) disulfide 0
                                    Bis(2-methyl-3-furanyl)tetrasulfide 0
                                    Brasilamide E 0
                                    Camellimidazole D 0
                                    Camellimidazole F 0
                                    Di-2-furanylmethane 0
                                    Diproximicin A 0
                                    E-2-Methyl-5-(fur-3-yl)-pent-2-enal 0
                                    Elsholtzidiol 0
                                    Ethyl 3-[(2-furanylmethyl)thio]propanoate 0
                                    Ethyl 3-thiopheneacetate 0
                                    Furfuryl 2-methyl-3-furyl disulfide 0
                                    Furfuryl acetate 0
                                    Furfuryl propyl disulfide 0
                                    Furfuryl thioacetate 0
                                    Heptemerone C 0
                                    Isoavocadienofuran 0
                                    N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                                    N-(2-adamantyl)-4-bromo-1-methyl-3-pyrazolecarboxamide 0
                                    N-(2-cyano-1-cyclopentenyl)-1-ethyl-3-pyrazolecarboxamide 0
                                    N-(2-furylmethyl)-N'-isobutylthiourea 0
                                    N-(2-furylmethyl)thiourea 0
                                    N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-2-furancarboxamide 0
                                    N-(2-thienylmethyl)hydrazine-1-carbothioamide 0
                                    N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide 0
                                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(2-methylpropyl)-3-isoxazolecarboxamide 0
                                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide 0
                                    N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                                    N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-3-isoxazolecarboxamide 0
                                    N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                                    N-(4-cyano-2-methyl-3-pyrazolyl)-5-(4-methylphenyl)-3-isoxazolecarboxamide 0
                                    N-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-2-furancarboxamide 0
                                    N-(5-chloro-2-pyridinyl)-2-ethyl-3-pyrazolecarboxamide 0
                                    N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                                    N-(6-tert-butyl-3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                                    N-Cyclohexyl-5-(2-thienyl)-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,4aR,12aR)-2-[2-(ethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-(propylamino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aS,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[1-(2-furanyl)ethylideneamino]carbamic acid tert-butyl ester 0
                                    N-[1-[(4-fluorophenyl)methyl]-3,5-dimethyl-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                                    N-[1-[(4-fluorophenyl)methyl]-3-pyrazolyl]-5-methyl-2-furancarboxamide 0
                                    N-[1-[(4-fluorophenyl)methyl]-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                                    N-[2-(1-cyclohexenyl)ethyl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[4-(3,4-dimethylphenyl)-2-thiazolyl]-2-furancarboxamide 0
                                    N-[4-(4-chlorophenyl)-2-thiazolyl]-N-[3-(diethylamino)propyl]-2-furancarboxamide 0
                                    N-\{2-[(4-chlorobenzyl)thio]ethyl\}-2-furamide 0
                                    N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                                    N-cyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                                    N-cyclopropyl-5-thiophen-2-yl-3-isoxazolecarboxamide 0
                                    N-ethyl-2-Furancarboxamide 0
                                    N-phenethyl-2-furamide 0
                                    N1-(2-furylmethyl)-2-cyanoacetamide 0
                                    Netropsin Dihydrochloride 0
                                    Oxonol 0
                                    PD 125375 0
                                    Penicillilactone A 0
                                    Phaeofuran A 0
                                    Proximicin A 0
                                    Proximicin F 0
                                    Proximicin G 0
                                    Pyrrole-2-carboxamide 0
                                    S-(2-Furanylmethyl) methanethioate 0
                                    S-(2-Furanylmethyl) propanethioate 0
                                    TAN-868 A 0
                                    Thiophene-2-thiol 0
                                    Thiophene-3-carbothioamide 0
                                    Trichocitrin 0
                                    [4-[1-(1-cyclopentyl-5-tetrazolyl)propyl]-1-piperazinyl]-(2-furanyl)methanone 0
                                    alpha-Methyl-2-furanacrolein 0
                                    azaarene + 0
                                    ethylmethylthiambutene 0
                                    heteroaryl group + 0
                                    hydracarbazine 0
                                    imidazopyrimidine + 21
                                    monocyclic heteroarene + 170
                                    nucleobase-containing molecular entity + 5
                                    penthienate 0
                                    polycyclic heteroarene + 8
                                    pteridines + 0
                                    rufinamide 0
                                    tetrapyrrole + 0
paths to the root